Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Miniaturized Matrixed Enthalpy Metter - Portable, affordable, easy to operate, diagnostic device enabling a rapid & accurate diagnosis of a patient infected by antibiotic-resistant bacteria

Project description

A portable device for fast diagnosis of antibiotic-resistant bacteria

The rising incidence of antibiotic-resistant bacteria and their potential for transmission between patients is a threat not adequately diagnosed by the usual sample-taking methods. Project MMEM – the Miniaturized Matrixed Enthalpy-Meter portable device – allows fast and accurate diagnosis of carbapenem-resistant Enterobacteriaceae (CRE) without time-consuming laboratory analysis. Based on measuring enthalpy, the heat released between a pyroelectric sensor and a DNA sample, MMEM allows doctors at hospitals and private practice to take immediate action, such as ensuring patient isolation immediately. The project plans a European clinical study for validation and a pilot phase introduction in the Israeli market, after which it will target a 15 % share in the CRE diagnosis market.

Objective

Miniaturized Matrixed Enthalpy-Meter (MMEM) - a diagnostic device for a rapid and accurate diagnosis of antibiotic resistant bacteria to be used in emergency rooms, clinical laboratories, doctor offices, and other point-of-care locations.
GenoSmart, is developing a novel bio-electronic molecular detection system for detection the presence of a pathogenic DNA is a biologic sample obtained from a patient. In particularly the system allows immediate detection of Carbapenem-resistant bacteria which have developed a resistance to all kinds of known antibiotics. The technology is based on a pyroelectric sensor onto a suspected DNA sample is immobilized. The system utilizes heat release during hybridization of complementary DNA molecules. If a successful hybridization between the sensor and the suspected sample molecules occurs, enthalpy (the internal energy) is released in the form of a detectable heat. The sensor immediately detects this released heat and transduces it to an electric signal. Following this detection, the result is displayed to the operator, and a decision if to isolate the patient from other patients is made. In contrast to currently available molecular detection techniques, GenoSmart MMEM device fulfills the essential need for a rapid and accurate diagnosis tool, along with a cost-effective test and without any dependency on labs and complicated facilities.The ultimate objective is to make GenoSmart's MMEM ready for market launch in Europe. This entails a number of technical and strategic objectives, including the completion of the product’s CRE detection capability, the clinical validation through a European clinical study, and the exploitation of its results (IP expansion, commercial agreements with distributors etc.).
The Company plans to start sales in 2020, first in Israel as a pilot market, and gradually reaching solid penetration rate 15% of the CRE diagnosis market within 7 years.

Keywords

Programme(s)

Topic(s)

Funding Scheme

SME-2 - SME instrument phase 2

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-EIC-SMEInst-2018-2020

See all projects funded under this call

Coordinator

GENOSMART LTD
Net EU contribution
€ 2 315 639,00
Address
10, JULIELMO MARCONI STREET
3295524 Haifa
Israel
SME
Yes
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 3 308 056,00